Unknown

Dataset Information

0

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.


ABSTRACT:

Background

Preclinical models have reported a synergistic interaction between sorafenib and vinorelbine. We investigated the toxicity, efficacy, and pharmacokinetics interaction of this combination as first-line treatment for patients with metastatic breast cancer.

Methods

Patients were HER2-negative and treated with vinorelbine 30 mg/m2 IV days 1,8 every 21 plus daily oral sorafenib. In the phase I portion (3+3 design) patients received sorafenib 200 mg BID (cohort 1) or 400 mg BID (cohort 2). In the phase II expansion, 21 more evaluable patients were planned to receive the maximum tolerated dose (MTD). Pharmacokinetic analysis was performed in 6 patients: blood concentrations were compared for each drug in the presence or absence of the other drug.

Results

In cohort 1, one patient experienced a dose-limiting toxicity (DLT) (grade 3 pancreatitis), requiring the expansion of this cohort to 6 patients, without further documented DLTs. In cohort 2, one patient of six experienced a grade 4 DLT (asymptomatic rise in amylase not requiring drug discontinuation), establishing this dose level as the MTD (sorafenib 400 mg BID). After expansion at the MTD, a total of 27 patients (median age 57) were treated for a median of 8 cycles. One grade 5 febrile neutropenia occurred. With repeated cycles, 52% of patients required at least 1 dose reduction of either drug. One patient experienced a sustained grade 3 fatigue resulting in treatment discontinuation. The response rate was 30%. Median PFS was 5.7 months (95% CI 4.4-7.6), and clinical benefit (absence of disease progression at 6 months) was 48%. PK analysis showed a significant interaction between the two drugs, resulting in a higher Cmax of vinorelbine in the presence of sorafenib.

Conclusion

The combination of sorafenib and vinorelbine at full doses is feasible but not devoid of toxicity, likely also due to a significant PK interaction.

Trial registration

ClinicalTrials.gov NCT00764972.

SUBMITTER: Ferrario C 

PROVIDER: S-EPMC5167316 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.

Ferrario Cristiano C   Strepponi Ivan I   Esfahani Khashayar K   Charamis Helen H   Langleben Adrian A   Scarpi Emanuela E   Nanni Oriana O   Miller Wilson H WH   Panasci Lawrence C LC  

PloS one 20161219 12


<h4>Background</h4>Preclinical models have reported a synergistic interaction between sorafenib and vinorelbine. We investigated the toxicity, efficacy, and pharmacokinetics interaction of this combination as first-line treatment for patients with metastatic breast cancer.<h4>Methods</h4>Patients were HER2-negative and treated with vinorelbine 30 mg/m2 IV days 1,8 every 21 plus daily oral sorafenib. In the phase I portion (3+3 design) patients received sorafenib 200 mg BID (cohort 1) or 400 mg B  ...[more]

Similar Datasets

| S-EPMC4447850 | biostudies-literature
| S-EPMC8484172 | biostudies-literature
| S-EPMC5448660 | biostudies-literature
| S-EPMC2395340 | biostudies-other
| S-EPMC4622533 | biostudies-literature
| S-EPMC5655999 | biostudies-literature
| S-EPMC9489776 | biostudies-literature
| S-EPMC4391774 | biostudies-literature
| S-EPMC6964136 | biostudies-literature
| S-EPMC3907671 | biostudies-literature